Germantown, TNNCT06759649Now EnrollingIRB Ready

Neoplasm Clinical Trial in Germantown, TN

Access cutting-edge neoplasm treatment through this clinical trial at a research site in Germantown. Study-provided care at no cost to qualified participants.

Sponsored by Compugen Ltd

Quick Self-Assessment

See if you qualify for this Germantown location

Preparing your pre-screening questions…

Expert Care in Germantown

Access neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasm treatment provided free

Apply for This Germantown Location

Check if you qualify for this neoplasm clinical trial in Germantown, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Germantown

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Germantown site if eligible
  4. 4Begin participation

About This Neoplasm Study in Germantown

The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

Sponsor: Compugen Ltd

Who Can Participate

Inclusion Criteria

Participants with histologically/cytologically confirmed advanced recurrent or metastatic solid tumor malignancy
Part 1 (dose escalation): Participants must have had disease progression on or following all available standard of care (SOC) therapies known to confer clinical benefit.
Part 2 (dose expansion): Participants may be enrolled following disease progression that has progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized SOC.
Participants must have a solid tumor measurable by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria by investigator assessment

Exclusion Criteria

History of another malignancy within 2 years prior to the first trial intervention administration (unless the malignancy was treated with curative intent with low risk of recurrence \[e.g., nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar\] which are allowed to enroll).
Therapy with Immunosuppressive doses of systemic medications, such as steroids (doses \>10 mg/day prednisone or equivalent daily) within 2 weeks before trial intervention administration
Have known active central nervous system (CNS) metastases and/or leptomeningeal disease (LMD).
Active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.
Ascites or pleural effusion that is symptomatic and/or requiring drainage within 2 weeks prior to the first trial intervention administration.
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or participants with human immunodeficiency virus (HIV).
Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the participant's participation in the trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Germantown?

Yes, this clinical trial (NCT06759649) has an active research site in Germantown, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasm Treatment Options in Germantown, TN

If you're searching for neoplasm treatment options in Germantown, TN, this clinical trial (NCT06759649) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Germantown research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasm clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Germantown, TN

See all breast cancer clinical trials recruiting in Germantown — not just this study.

Browse Breast Cancer Trials in Germantown →

Browse More Trials by Condition

Breast Cancer TrialsProstate Cancer TrialsOvarian Cancer TrialsMultiple Myeloma TrialsEndometrial Cancer TrialsMyeloproliferative Neoplasms TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Germantown?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Germantown, TN